• Mashup Score: 0

    Sirnaomics Ltd. (the “Company”, Stock Code: 2257.HK, together with its subsidiaries, the “Group” or “Sirnaomics”), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced the Group has completed all dosing regimens for its Phase I study of STP707 for the treatment of multiple solid tumors in patients with various types of late-stage cancers who did not respond to multiple rounds of other oncology treatments. Approximately 74% of evaluable patients d

    Tweet Tweets with this article
    • Excited to see these results released and happy we were part of this study through our PI @DrAngelaAlistar We (@AtlanticHealth ) eagerly await next steps with this agent. https://t.co/vxsW77eAtD

  • Mashup Score: 0

    Awe-inspiring science reporting, technology news, and DIY projects. Skunks to space robots, primates to climates. That’s Popular Science, 145 years strong.

    Tweet Tweets with this article
    • Nice #melanoma article from @PopSci featuring a few quotes from a very astute @AtlanticHealth clinician and researcher: 5 skin cancer prevention and treatment technologies | Popular Science (https://t.co/1doaHQ13dL)